Cargando…

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia

BACKGROUND: Clozapine is the treatment of choice in refractory psychosis. In most countries, clozapine must be stopped indefinitely if white blood cells fall below a defined threshold during routine monitoring. Despite evidence of severe adverse consequences of clozapine discontinuation, published a...

Descripción completa

Detalles Bibliográficos
Autores principales: Oloyede, Ebenezer, Dunnett, Danielle, Taylor, David, Clark, Ivana, MacCabe, James H, Whiskey, Eromona, Onwumere, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249299/
https://www.ncbi.nlm.nih.gov/pubmed/37291505
http://dx.doi.org/10.1186/s12888-023-04902-w
Descripción
Sumario:BACKGROUND: Clozapine is the treatment of choice in refractory psychosis. In most countries, clozapine must be stopped indefinitely if white blood cells fall below a defined threshold during routine monitoring. Despite evidence of severe adverse consequences of clozapine discontinuation, published accounts on the lived experiences and perspectives of patients and carers are scarce. METHOD: We completed semi-structured interviews with patients (n = 4) and family carers (n = 4) on experiences of clozapine cessation following suspected drug-induced neutropenia. Interviews were audio-recorded, transcribed and analysed thematically. RESULTS: The two overarching themes comprised:(i) stress of clozapine below threshold neutrophil results and (ii) patient and carer priorities. CONCLUSIONS: There is a suggested need for evidence-based pharmacological and psychological approaches to support patients and carers after clozapine cessation. Such approaches will minimise the potentially negative physical and emotional sequela in the aftermath of a below threshold neutrophil result and reduce the likelihood of experiencing additional health and social inequalities after clozapine discontinuation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-023-04902-w.